Literature DB >> 19783905

A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?

Andrew D Rhim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19783905      PMCID： PMC3720128          DOI： 10.4161/cbt.8.20.9810

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  6 in total

1.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.

Authors:  M Grewe; F Gansauge; R M Schmid; G Adler; T Seufferlein
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

2.  In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft.

Authors:  V D Courtenay; I E Smith; M J Peckham; G G Steel
Journal:  Nature       Date:  1976-10-28       Impact factor: 49.962

3.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

4.  Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.

Authors:  Qing Chang; Eric Chen; David W Hedley
Journal:  Cancer Biol Ther       Date:  2009-10-06       Impact factor: 4.742

5.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

6.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728
  6 in total
  2 in total

Review 1.  Molecular targeted approaches for treatment of pancreatic cancer.

Authors:  Z Q Huang; A K Saluja; V Dudeja; S M Vickers; D J Buchsbaum
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.

Authors:  Maria Rovithi; Amir Avan; Niccola Funel; Leticia G Leon; Valentina E Gomez; Thomas Wurdinger; Arjan W Griffioen; Henk M W Verheul; Elisa Giovannetti
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.